[Anonymous (2009). Cystic fibrosis transmembrane conductance regulator.[PUBMED]]Search in Google Scholar
[Bobadilla, J., L., Farrell, M.H., Farrell, P.M. (2002). Applying CFTR molecular genetics to facilitate the diagnosis of cystic fibrosis through screening. Adv. Pediatr., 49, 131-190.]Search in Google Scholar
[Corbetta, C., Seia, M., Bassotti, A., Ambrosioni, A., Giunta, A., Padoan, R. (2002). Screening for cystic fibrosis in newborn infants: Results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population. J. Med. Screen, 60-63.10.1136/jms.9.2.60]Search in Google Scholar
[Ferec, C., Casals, T., Chuzhanova, N., Macek, M., Bienvenu, T. (2006). Gross genomic rearrangements involving deletions in the CFTR gene: Characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of the underlying mechanisms. Eur. J. Hum. Genet, 14, 567-576.10.1038/sj.ejhg.5201590]Search in Google Scholar
[Hammond, K.B., Abman, S.H., Sokol, R.J., Accurso, F.J. (1991). Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. New Eng. J. Med., 769-774.10.1056/NEJM199109123251104]Search in Google Scholar
[Kerem, B.S., Buchanan, J.A., Durie, P., Corey, M.L., Levison, H., Rommens, J.M., Buchwald, M., Tsui, L.C. (1989). DNA marker haplotype association with pancreatic insufficiency in cystic fibrosis. Amer. J. Hum. Genet, 44, 827-834.]Search in Google Scholar
[Kloosterboer, M., Hoffman, G., Rock, M., Gershan, W., Laxova, A., Li, Z., Farrell, P. (2009). Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics, 338-346.10.1542/peds.2008-1681]Search in Google Scholar
[Krumina, A., Kroshkina, V., Krumina, L., Svabe, V., Krumina, Z., Tamane, I., Baumanis, V. (2001). Cystic fibrosis mutation dF508 in the Latvian population. RSU/AML Scientific Proceedings, 161-166.]Search in Google Scholar
[Loeber, J.G. (2007). Neonatal screening in Europe; the situation in 2004. J. Inherit. Metab. Dis., 30, 430-438.]Search in Google Scholar
[Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. (2001). Cystic fibrosis. In: The Metabolic and Molecular bases of Inherited Disease. New York: McGraw-Hill Medical Publishing Division, 8th edition, Vol. 3, 5121-5173.]Search in Google Scholar
[Sims, E.J., Clark, A., McCormick, J., Mehta, G., Connett, G., Mehta, A. (2007). United Kingdom Cystic Fibrosis Database Steering Committee. Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics, 119(1), 19-28.]Search in Google Scholar
[Svabe, V., Krumina, A. (2001). Latvijas Cistiskās fibrozes slimnieku klīniskā stāvokła novērtējums [Evaluation of CF patients' clinical symptoms in Latvia]. RSU/AML Scientific Proceedings, 128-130.]Search in Google Scholar
[Wilcken, B., Wiley, V. (2003). Newborn screening methods for cystic fibrosis. Paediatr. Respir. Rev., 272-277.10.1016/S1526-0542(03)00084-8]Search in Google Scholar
[Znotina, I., Svabe, V., Teibe U. (2006). Cistiskās fibrozes slimnieku dzīvildzes izmaiņas Latvijā atkarībā no terapijas [Therapy influence to life expectancy of CF patients in Latvia]. RSU/AML Scientific Proceedings, 345-349.]Search in Google Scholar